OLMA (Olema Pharmaceuticals) Change In Receivables : $0.00 Mil (TTM As of Sep. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Olema Pharmaceuticals Change In Receivables?

Olema Pharmaceuticals's change in receivables for the quarter that ended in Sep. 2024 was $0.00 Mil. It means Olema Pharmaceuticals's Accounts Receivable stayed the same from Jun. 2024 to Sep. 2024 .

Olema Pharmaceuticals's change in receivables for the fiscal year that ended in Dec. 2023 was $0.00 Mil. It means Olema Pharmaceuticals's Accounts Receivable stayed the same from Dec. 2022 to Dec. 2023 .

Olema Pharmaceuticals's Accounts Receivable for the quarter that ended in Sep. 2024 was $0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Olema Pharmaceuticals's liquidation value for the three months ended in Sep. 2024 was $183.50 Mil.

Olema Pharmaceuticals Change In Receivables Historical Data

The historical data trend for Olema Pharmaceuticals's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Olema Pharmaceuticals Change In Receivables Chart

Olema Pharmaceuticals Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

Olema Pharmaceuticals Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Change In Receivables	Get a 7-Day Free Trial															-	-	-	-	-

Olema Pharmaceuticals Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Olema Pharmaceuticals (NAS:OLMA) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Olema Pharmaceuticals's Days Sales Outstanding for the quarter that ended in Sep. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0	*	91
=

2. In Ben Graham's calculation of liquidation value, Olema Pharmaceuticals's accounts receivable are only considered to be worth 75% of book value:

Olema Pharmaceuticals's liquidation value for the quarter that ended in Sep. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	214.763	-	31.262	+	0.75 * 0	+	0.5 * 0
=	183.50

Olema Pharmaceuticals Change In Receivables Related Terms

Thank you for viewing the detailed overview of Olema Pharmaceuticals's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Olema Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Olema Pharmaceuticals inc (NAS:OLMA) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

780 Brannan Street, San Francisco, CA, USA, 94103

Website

https://www.olema.com

Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.

Executives

Paradigm Biocapital Advisors Lp	10 percent owner	767 THIRD AVENUE, 17TH FLOOR, NEW YORK NY 10017
Cyrus Harmon	director, officer: Chief Technology Officer	C/O OLEMA PHARMACEUTICALS, INC., 512 2ND STREET, 4TH FLOOR, SAN FRANCISCO CA 94107
G. Walmsley Graham	director	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Kovacs Shane William Charles	officer: Ch. Operating & Financial Off.	PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080
Naseem Zojwalla	officer: Chief Medical Officer	C/O OLEMA PHARMACEUTICALS, INC., 512 2ND STREET, 4TH FLOOR, SAN FRANCISCO CA 94107
Sean Bohen	director, officer: President and CEO	C/O OLEMA PHARMACEUTICALS, INC., 512 2ND STREET, 4TH FLOOR, SAN FRANCISCO CA 94107
David C. Myles	officer: Chief Development Officer	C/O OLEMA PHARMACEUTICALS, INC., 512 2ND STREET, 4TH FLOOR, SAN FRANCISCO CA 94107
J. Scott Garland	director	210 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
Senai Asefaw	10 percent owner	767 THIRD AVENUE, 17TH FLOOR, NEW YORK CITY NY 10017
Paradigm Biocapital International Fund Ltd.	10 percent owner	C/O WALKERS CORPORATE LIMITED, 190 ELGIN AVENUE, GEORGE TOWN, GRAND CAYMAN E9 KY1-9008
Biotechnology Value Fund L P	10 percent owner	44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Paradigm Biocapital Advisors Gp Llc	10 percent owner	767 THIRD AVENUE, 17TH FLOOR, NEW YORK CITY NY 10017
Kinney Horn	officer: Chief Business Officer	C/O OLEMA PHARMACEUTICALS, INC., 512 2ND STREET, 4TH FLOOR, SAN FRANCISCO CA 94107
Yi Larson	director	C/O RAYZEBIO, INC., 5505 MOREHOUSE DRIVE, SUITE 300, SAN DIEGO CA 92121
Cormorant Asset Management, Lp	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116